🔗 Share this article

The Nobel Prize in medical science was granted for transformative findings that illuminate how the body's defense network targets harmful pathogens while protecting the healthy tissues.

A trio of esteemed researchers—from Japan Shimon Sakaguchi and American experts Mary Brunkow and Dr. Ramsdell—share this honor.

The work identified unique "security guards" within the immune system that eliminate malfunctioning immune cells capable of attacking the organism.

The findings are now enabling innovative treatments for immune disorders and cancer.

The winners will divide a monetary award worth 11 million Swedish kronor.

Decisive Findings

"Their research has been essential for understanding how the immune system operates and why we do not all suffer from serious self-attack conditions," stated the chair of the Nobel Committee.

This team's studies address a fundamental mystery: How does the defense system protect us from numerous infections while leaving our healthy cells intact?

The body's protection system employs immune cells that search for indicators of infection, including viruses and germs it has never encountered.

Such defenders employ sensors—known as recognition units—that are produced randomly in countless variations.

This gives the immune system the capacity to fight a wide array of threats, but the unpredictability of the mechanism inevitably creates immune cells that may target the host.

Security Guards of the Immune System

Scientists earlier understood that some of these problematic defense cells were destroyed in the thymus—where immune cells develop.

This year's Nobel Prize honors the discovery of regulatory T-cells—described as the immune system's "security guards"—which patrol the system to disarm any defenders that assault the body's own tissues.

We know that this process fails in autoimmune diseases such as juvenile diabetes, MS, and RA.

The prize committee added, "The discoveries have established a new field of investigation and spurred the development of innovative treatments, for instance for cancer and immune disorders."

In malignancies, T-regs prevent the body from attacking the growth, so research are focused on lowering their numbers.

For autoimmune diseases, experiments are testing boosting T-reg cells so the body is no longer being harmed. A comparable method could also be effective in minimizing the chances of organ transplant rejection.

Pioneering Studies

Professor Shimon Sakaguchi, from a Japanese institution, conducted tests on mice that had their thymus removed, leading to self-attack conditions.

The researcher showed that injecting defense cells from healthy mice could stop the illness—implying there was a mechanism for preventing immune cells from harming the host.

Dr. Brunkow, affiliated with the a research center in Seattle, and Fred Ramsdell, now at Sonoma Biotherapeutics in San Francisco, were investigating an inherited immune disorder in mice and people that resulted in the discovery of a gene vital for the way regulatory T-cells operate.

"Their groundbreaking work has revealed how the immune system is kept in check by regulatory T cells, preventing it from accidentally targeting the body's own tissues," commented a leading physiology expert.

"This research is a striking example of how fundamental biological study can have broad consequences for human health."